Immune cell metabolism changes may underlie PAH inflammation, which could inform targets for new PAH treatment strategies.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

People with portopulmonary hypertension (PoPH) show lower survival rates than other PAH types, but targeted PAH treatments ...